Dynogen's Prokinetic Drug, DDP733, Enters Phase 2b For Irritable Bowel Syndrome WithInformation on Dynogen's Prokinetic Drug, DDP733, Enters Phase 2b For Irritable Bowel Syndrome With under Irritable Bowel Syndrome section of the Health Articles & Reviews; Dynogen Pharmaceuticals, Inc. announced that the first patients have been dosed in a Phase 2b trial of DDP733 (pumosetrag) as a treatment for irritable bowel ... |
 |
|
Dynogen's Prokinetic Drug, DDP733, Enters Phase 2b For Irritable Bowel Syndrome With
by Anthony F Boyle 11-11-2007, 03:42 AM
Dynogen Pharmaceuticals, Inc. announced that the first patients have been dosed in a Phase 2b trial of DDP733 (pumosetrag) as a treatment for irritable bowel syndrome with constipation (IBS-c). This DDP733 Phase 2b trial is a randomized, double-blind, placebo controlled study that is enrolling female patients with IBS-c at multiple centers in the U.S. and Canada. [click link for full article]
More... |
Views 25
Comments 0
|
|
| Bookmarks |
| Currently Active Users Viewing This Article: 1 (0 members and 1 guests) | |
| Article Tools | |
| Display Modes | |
|
|
 |  |  |  |
 |  |  |  |
 |  |  |  |
 |  |  |  |
 |  |  |  |
Linear Mode
